Company:  PACIRA BIOSCIENCES, INC. (PCRX)
Form Type:  S-8
Filing Date:  8/8/2019 
CIK:  0001396814 
Address:  5 SYLVAN WAY
SUITE 300
 
City, State, Zip:  PARSIPPANY, New Jersey 07054 
Telephone:  973-254-3560 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$42.92  
Change: 
0.34 (0.80%)  
Trade Time: 
Nov 15  
Market Cap: 
$1.79B
Trade PCRX now with 

© 2019  
Description of Business
Pacira Pharmaceuticals, Inc., a Delaware corporation, is the holding company for our California operating subsidiary of the same name, or Pacira California. In March 2007, we acquired Pacira California from SkyePharma Holdings, Inc. (now a subsidiary of Vectura Group plc), or Skyepharma (referred to in this Annual Report on Form 10-K as the "Skyepharma Acquisition"). Unless the context requires otherwise, references to "Pacira," "we," the "Company," "us" and "our" in this Annual Report on Form 10-K refers to Pacira Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries. Corporate Information We were incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed our name to Pacira, Inc. in June 2007. In October 2010, we changed our name to Pacira Pharmaceuticals, Inc. Our principal executive offices are in Parsippany, New Jersey. Pacira®, EXPAREL®, DepoFoam®, DepoCyt® (United States (U.S.
Register and access this filing in:     
  FORM S-8
    CALCULATION OF REGISTRATION FEE
    EXPLANATORY NOTE
    PART II
      Item 3. Incorporation of Documents by Reference.
    Item 4. Description of Securities.
    Item 5. Interests of Named Experts and Counsel.
      Item 6. Indemnification of Directors and Officers.
      Item 7. Exemption from Registration Claimed.
      Item 8. Exhibits.
      Item 9. Undertakings.
    SIGNATURES
    POWER OF ATTORNEY
  EXHIBIT 5.1
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 23.2
    Consent of Independent Auditors